Header Logo

Connection

CARL ALLEN to Child

Back to Details
This is a "connection" page, showing publications CARL ALLEN has written about Child.
CARL ALLEN
Connection Strength
1.113
Child
  1. BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025 Jul 10; 146(2):206-218.
    View in: PubMed
    Score: 0.057
  2. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 05 16; 143(20):2053-2058.
    View in: PubMed
    Score: 0.052
  3. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024 05 14; 8(9):2248-2258.
    View in: PubMed
    Score: 0.052
  4. Unswitched memory B cell deficiency in children with sickle cell disease and response to pneumococcal polysaccharide vaccine. Am J Hematol. 2024 06; 99(6):1084-1094.
    View in: PubMed
    Score: 0.052
  5. Histiocytic Disorders of Childhood. Pediatr Rev. 2022 Oct 01; 43(10):561-571.
    View in: PubMed
    Score: 0.047
  6. IFN-? signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Blood Adv. 2021 09 14; 5(17):3457-3467.
    View in: PubMed
    Score: 0.043
  7. Building a better blast-trap. Pediatr Hematol Oncol. 2020 02; 37(1):1-4.
    View in: PubMed
    Score: 0.039
  8. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood. 2018 09 27; 132(13):1438-1451.
    View in: PubMed
    Score: 0.035
  9. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.034
  10. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017 05 01; 109(5).
    View in: PubMed
    Score: 0.032
  11. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.031
  12. Pediatric lymphomas and histiocytic disorders of childhood. Pediatr Clin North Am. 2015 Feb; 62(1):139-65.
    View in: PubMed
    Score: 0.027
  13. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014 Nov; 165(5):990-6.
    View in: PubMed
    Score: 0.027
  14. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010 Apr 15; 184(8):4557-67.
    View in: PubMed
    Score: 0.020
  15. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010 Mar; 54(3):416-23.
    View in: PubMed
    Score: 0.019
  16. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008 Jun; 50(6):1227-35.
    View in: PubMed
    Score: 0.017
  17. Evaluating the Implementation Success of an Intensity-Adapted Guideline for Pediatric Acute Myeloid Leukemia in Malawi: An Observational-Implementation Study Protocol. Pediatr Blood Cancer. 2025 Nov; 72(11):e32005.
    View in: PubMed
    Score: 0.014
  18. Relapse patterns among children and adolescents with Kaposi sarcoma in Malawi. Pediatr Hematol Oncol. 2025 Aug; 42(5):276-286.
    View in: PubMed
    Score: 0.014
  19. High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi. JCO Glob Oncol. 2025 Mar; 11:e2400591.
    View in: PubMed
    Score: 0.014
  20. Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Arthritis Rheumatol. 2025 Feb; 77(2):226-238.
    View in: PubMed
    Score: 0.013
  21. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.013
  22. Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Blood Adv. 2024 03 12; 8(5):1116-1127.
    View in: PubMed
    Score: 0.013
  23. Role of non-chromosomal birth defects on the risk of developing childhood Hodgkin lymphoma: A Children's Oncology Group study. Pediatr Blood Cancer. 2024 Mar; 71(3):e30822.
    View in: PubMed
    Score: 0.013
  24. Pediatric HIV+ Kaposi sarcoma exhibits clinical, virological, and molecular features different from the adult disease. JCI Insight. 2023 11 22; 8(22).
    View in: PubMed
    Score: 0.013
  25. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis Rheumatol. 2023 10; 75(10):1714-1732.
    View in: PubMed
    Score: 0.012
  26. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023 10; 82(10):1271-1285.
    View in: PubMed
    Score: 0.012
  27. Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30565.
    View in: PubMed
    Score: 0.012
  28. Addressing the childhood cancer crisis in sub-Saharan Africa. Lancet Oncol. 2023 07; 24(7):729-732.
    View in: PubMed
    Score: 0.012
  29. Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
    View in: PubMed
    Score: 0.012
  30. Outcomes of Wilms tumor therapy in Lilongwe, Malawi, 2016-2021: Successes and ongoing research priorities. Pediatr Blood Cancer. 2023 05; 70(5):e30242.
    View in: PubMed
    Score: 0.012
  31. Acute liver failure and unique challenges of pediatric liver transplantation amidst a worldwide cluster of adenovirus-associated hepatitis. Am J Transplant. 2023 01; 23(1):93-100.
    View in: PubMed
    Score: 0.012
  32. Divergent clinical presentations and outcomes among children and adolescents with Kaposi sarcoma in Malawi and Tanzania. HIV Med. 2023 06; 24(6):664-675.
    View in: PubMed
    Score: 0.012
  33. Neuroimaging in Pediatric Patients with Juvenile Xanthogranuloma of the CNS. AJNR Am J Neuroradiol. 2022 11; 43(11):1667-1673.
    View in: PubMed
    Score: 0.012
  34. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022 12; 177:120-142.
    View in: PubMed
    Score: 0.012
  35. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245.
    View in: PubMed
    Score: 0.011
  36. Prevalence of the BRAFV600E mutation in Greek adults with Langerhans cell histiocytosis. Pediatr Hematol Oncol. 2022 Sep; 39(6):540-548.
    View in: PubMed
    Score: 0.011
  37. Long-term outcomes for children and adolescents with Kaposi sarcoma. HIV Med. 2022 02; 23(2):197-203.
    View in: PubMed
    Score: 0.011
  38. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
    View in: PubMed
    Score: 0.011
  39. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021 04 29; 137(17):2337-2346.
    View in: PubMed
    Score: 0.011
  40. Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa. Blood Adv. 2020 08 25; 4(16):4007-4019.
    View in: PubMed
    Score: 0.010
  41. Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma. Leuk Lymphoma. 2020 10; 61(10):2419-2427.
    View in: PubMed
    Score: 0.010
  42. Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 2020 03; 188(6):e84-e87.
    View in: PubMed
    Score: 0.010
  43. Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome-like Clinical Presentation in Human Immunodeficiency Virus-infected Children in Malawi. Clin Infect Dis. 2019 11 13; 69(11):2022-2025.
    View in: PubMed
    Score: 0.010
  44. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695.
    View in: PubMed
    Score: 0.009
  45. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 11; 66(11):e27929.
    View in: PubMed
    Score: 0.009
  46. A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America. Pediatr Blood Cancer. 2019 08; 66(8):e27798.
    View in: PubMed
    Score: 0.009
  47. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
    View in: PubMed
    Score: 0.009
  48. Capacity building: a novel pediatric hematology-oncology fellowship program in sub-Saharan Africa. Blood Adv. 2018 11 30; 2(Suppl 1):11-13.
    View in: PubMed
    Score: 0.009
  49. Hepatobiliary Dysfunction and Disseminated Intravascular Coagulation Increase Risk of Mortality in Pediatric Hemophagocytic Lymphohistiocytosis. Pediatr Crit Care Med. 2018 10; 19(10):e522-e530.
    View in: PubMed
    Score: 0.009
  50. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018 08; 28(8):521-528.
    View in: PubMed
    Score: 0.009
  51. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100.
    View in: PubMed
    Score: 0.009
  52. Radiation pneumonitis in pediatric Hodgkin lymphoma patients receiving radiation therapy to the chest. Pract Radiat Oncol. 2018 Sep - Oct; 8(5):e364-e368.
    View in: PubMed
    Score: 0.008
  53. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
    View in: PubMed
    Score: 0.008
  54. PET/MR in the Assessment of Pediatric Histiocytoses: A Comparison to PET/CT. Clin Nucl Med. 2017 Aug; 42(8):582-588.
    View in: PubMed
    Score: 0.008
  55. Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget. 2017 Jul 11; 8(28):46065-46070.
    View in: PubMed
    Score: 0.008
  56. New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Mol Cancer. 2017 07 06; 16(1):115.
    View in: PubMed
    Score: 0.008
  57. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018 Feb; 36(1):307-315.
    View in: PubMed
    Score: 0.008
  58. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200.
    View in: PubMed
    Score: 0.008
  59. Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.008
  60. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
    View in: PubMed
    Score: 0.008
  61. Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. J Allergy Clin Immunol. 2017 01; 139(1):232-245.
    View in: PubMed
    Score: 0.008
  62. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
    View in: PubMed
    Score: 0.006
  63. The evolution of cellular deficiency in GATA2 mutation. Blood. 2014 Feb 06; 123(6):863-74.
    View in: PubMed
    Score: 0.006
  64. Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol. 2014 Apr; 31(3):253-7.
    View in: PubMed
    Score: 0.006
  65. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014 Mar; 61(3):479-87.
    View in: PubMed
    Score: 0.006
  66. Resection of mediastinal castleman's disease: a case report. Pediatr Hematol Oncol. 2013 Sep; 30(6):554-6.
    View in: PubMed
    Score: 0.006
  67. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
    View in: PubMed
    Score: 0.006
  68. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer. 2011 Jan; 56(1):154-5.
    View in: PubMed
    Score: 0.005
  69. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009 May; 52(5):621-5.
    View in: PubMed
    Score: 0.005
  70. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan; 52(1):97-101.
    View in: PubMed
    Score: 0.004
  71. Bicycle safety. Am J Dis Child. 1987 Feb; 141(2):136-7.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.